Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Recommendation of “Buy” by Analysts

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has been given a consensus recommendation of “Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $14.80.

A number of research analysts have recently issued reports on ACHV shares. Rodman & Renshaw started coverage on Achieve Life Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $12.00 price target on the stock. RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th.

Institutional Trading of Achieve Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of ACHV. SG Americas Securities LLC purchased a new stake in shares of Achieve Life Sciences during the third quarter worth about $54,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Achieve Life Sciences during the second quarter worth about $69,000. MetLife Investment Management LLC grew its position in shares of Achieve Life Sciences by 65.6% during the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,939 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Achieve Life Sciences during the third quarter worth about $113,000. Finally, Renaissance Technologies LLC grew its position in shares of Achieve Life Sciences by 134.2% during the second quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 14,360 shares in the last quarter. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Price Performance

Shares of ACHV stock opened at $3.11 on Wednesday. The stock has a market cap of $106.95 million, a price-to-earnings ratio of -2.75 and a beta of 1.66. The business’s fifty day moving average is $3.81 and its 200 day moving average is $4.36. Achieve Life Sciences has a twelve month low of $2.84 and a twelve month high of $5.59. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.10). During the same period in the previous year, the firm earned ($0.34) earnings per share. Research analysts expect that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.